No Picture
News

Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates

RAS is the most common oncogene implicated in human cancerKRAS, HRAS or NRAS mutations are present in approximately one-third of all cancer patients

CARLSBAD, Calif. , July 22, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen… […]

No Picture
News

Prescient Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening

Research will examine prevalent gut microbial markers present in colorectal cancer

CARLSBAD, Calif., June 2, 2020 /PRNewswire/ — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., announced today a research collaboration with … […]

No Picture
News

Qualigen Therapeutics Releases FastPack® SARS-CoV-2 Antibody Diagnostic Test to University of Louisville to Conduct Validation Studies

CARLSBAD, Calif., June 2, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the Company has released a pre-launch supply of its proposed FastPack® SARS-CoV-2 IgG Immunoassay diagnostic tes… […]